Oliver Donnelly
Overview
Explore the profile of Oliver Donnelly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis A, Bird A, Cowley L, Donnelly O, ELHaddad M, Evans C, et al.
Phys Med
. 2025 Feb;
131:104912.
PMID: 39954465
Purpose: To develop a phantom method of image quality assessment for radiotherapy planning CT protocols (head and neck (H&N) and prostate) and validate results against clinical image quality. Test with...
2.
Bopota K, Donnelly O, Borumandi F
J Craniofac Surg
. 2022 Nov;
34(3):e247-e249.
PMID: 36441840
Immune checkpoint inhibitors (ICI) have become an essential part of cancer treatment. Anti-programmed cell death receptor-1 (PD-1) is a monoclonal antibody that targets PD-1. For patients with inoperable cutaneous squamous...
3.
Feeney L, Jain Y, Beasley M, Donnelly O, Kong A, Moleron R, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503145
Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic chemotherapy. Recent phase II studies have reported improved...
4.
Brennan P, Lewthwaite R, Sakthithasan P, McGuigan S, Donnelly O, Alam P, et al.
J Oral Pathol Med
. 2020 Feb;
49(9):956-959.
PMID: 32017243
Aims: Oral and/or oropharyngeal acute mucositis during and after chemo-radiotherapy (chemo-RT) for head and neck squamous cell carcinoma (HNSCC) can be extremely painful, sometimes requiring nasogastric feeding to enable adequate...
5.
Jennings V, Scott G, Rose A, Scott K, Migneco G, Keller B, et al.
Mol Ther
. 2019 May;
27(6):1139-1152.
PMID: 31053413
A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and is now licensed for clinical...
6.
Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, et al.
Mol Ther
. 2014 Jul;
22(11):1936-48.
PMID: 25059678
Previously, we showed that vesicular stomatitis virus (VSV) engineered to express a cDNA library from human melanoma cells (ASMEL, Altered Self Melanoma Epitope Library) was an effective systemic therapy to...
7.
Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, et al.
Mol Ther
. 2014 Jun;
22(10):1851-63.
PMID: 24957982
Optimum clinical protocols require systemic delivery of oncolytic viruses in the presence of an intact immune system. We show that preconditioning with immune modulators, or loading virus onto carrier cells...
8.
Kottke T, Boisgerault N, Diaz R, Donnelly O, Rommelfanger-Konkol D, Pulido J, et al.
Nat Med
. 2013 Nov;
19(12):1625-1631.
PMID: 24240185
Tumor recurrence represents a major clinical challenge. Our data show that emergent recurrent tumors acquire a phenotype radically different from that of their originating primary tumors. This phenotype allows them...
9.
Donnelly O, Harrington K, Melcher A, Pandha H
J R Soc Med
. 2013 Jul;
106(8):310-4.
PMID: 23824333
Viruses that selectively replicate in cancer cells, leading to the death of the cell, are being studied for their potential as cancer therapies. Some of these viruses are naturally occurring...
10.
Donnelly O, Vile R, Pandha H, Harrington K, Melcher A
Oncotarget
. 2012 Sep;
3(8):735-6.
PMID: 22964541
No abstract available.